Halda Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer

Halda Therapeutics announced that the first patient has been dosed in the first-in-human Phase I/II clinical trial to evaluate the safety and tolerability of HLD-0915 in the treatment of metastatic CRPC.